The global market for CAR T-Cell Therapy was valued at US$ 5417 million in the year 2024 and is projected to reach a revised size of US$ 26750 million by 2031, growing at a CAGR of 26.0% during the forecast period.

CAR T-Cell Therapy Market

CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy) is an innovative form of immunotherapy that involves genetically modifying a patient’s own T cells to express a specific chimeric antigen receptor (CAR) on their surface. This receptor enables the T cells to target and destroy cancer cells effectively. CAR-T therapy has shown significant success in treating hematological malignancies, such as acute lymphoblastic leukemia (ALL) and certain types of lymphomas, and is being explored for its potential applications in solid tumors.

The CAR-T Cell Therapy market is primarily driven by its groundbreaking effectiveness in treating certain types of hematological malignancies, such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), particularly in patients who are refractory to standard treatments. The rising incidence of cancer globally and the growing demand for personalized and targeted therapies have further fueled market growth. In addition, advancements in genetic engineering and manufacturing processes are making CAR-T therapies safer, more efficient, and increasingly accessible. The strong support from government initiatives and private investments in oncology research is also accelerating the development of next-generation CAR-T products, expanding their therapeutic potential to include solid tumors.However, the market faces significant challenges, including the high cost of CAR-T therapies, which can exceed hundreds of thousands of dollars per treatment, making it inaccessible to many patients. The complex and time-consuming manufacturing process, which involves extracting and engineering a patient’s T cells, further contributes to these high costs. Additionally, CAR-T therapy is associated with severe side effects, such as cytokine release syndrome (CRS) and neurotoxicity, which require specialized management and can limit its broader adoption. Regulatory hurdles and the need for improved scalability also present obstacles, particularly in developing regions where healthcare infrastructure may be inadequate to support this advanced therapy.

The global top three CAR T-Cell therapy players include Novartis, Gilead Sciences, Bristol-Myers Squibb, with a total market share of more than 99%. The largest player is Gilead Sciences, with a market share of over 50%. North America is the global most important consumer market for CAR T-Cell therapy, with a market share of more than 65%. In terms of type, CD19-targeted CAR cell therapy has a market share of over 90%. In the field of application, the market share of lymphoma exceeds 90%.

This report aims to provide a comprehensive presentation of the global market for CAR T-Cell Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR T-Cell Therapy.

The CAR T-Cell Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global CAR T-Cell Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the CAR T-Cell Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of CAR T-Cell Therapy Market Report

Report Metric	Details
Report Name	CAR T-Cell Therapy Market
Accounted market size in year	US$ 5417 million
Forecasted market size in 2031	US$ 26750 million
CAGR	26.0%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	CD19 - Targeted BCMA - Targeted
Segment by Application	Lymphoma Multiple Myeloma
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), Autolus Therapeutics(Pipeline), Sorrento Therapeutics(Pipeline), Mustang Bio(Pipeline), Bluebird Bio(Pipeline), Cellectis(Pipeline), Allogene Therapeutics(Pipeline), Celyad(Pipeline)
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR T-Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is CAR T-Cell Therapy Market growing?

Ans: The CAR T-Cell Therapy Market witnessing a CAGR of 26.0% during the forecast period 2025-2031.

What is the CAR T-Cell Therapy Market size in 2031?

Ans: The CAR T-Cell Therapy Market size in 2031 will be US$ 26750 million.

What is the market share of major companies in CAR T-Cell Therapy Market?

Ans: The global top three CAR T-Cell therapy players include Novartis, Gilead Sciences, Bristol-Myers Squibb, with a total market share of more than 99%.

What is the Gilead Sciences share in CAR T-Cell Therapy Market?

Ans: The largest player is Gilead Sciences, with a market share of over 50%.

What is the CAR T-Cell Therapy Market share by region?

Ans: North America is the global most important consumer market for CAR T-Cell therapy, with a market share of more than 65%.

What is the CAR T-Cell Therapy Market share by type?

Ans: In terms of type, CD19-targeted CAR cell therapy has a market share of over 90%.

What is the CAR T-Cell Therapy Market share by application?

Ans: In the field of application, the market share of lymphoma exceeds 90%.

Who are the main players in the CAR T-Cell Therapy Market report?

Ans: The main players in the CAR T-Cell Therapy Market are Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), Autolus Therapeutics(Pipeline), Sorrento Therapeutics(Pipeline), Mustang Bio(Pipeline), Bluebird Bio(Pipeline), Cellectis(Pipeline), Allogene Therapeutics(Pipeline), Celyad(Pipeline)

What are the Application segmentation covered in the CAR T-Cell Therapy Market report?

Ans: The Applications covered in the CAR T-Cell Therapy Market report are Lymphoma, Multiple Myeloma

What are the Type segmentation covered in the CAR T-Cell Therapy Market report?

Ans: The Types covered in the CAR T-Cell Therapy Market report are CD19 - Targeted, BCMA - Targeted

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global CAR T-Cell Therapy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 CD19 - Targeted

1.2.3 BCMA - Targeted

1.3 Market by Application

1.3.1 Global CAR T-Cell Therapy Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Lymphoma

1.3.3 Multiple Myeloma

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global CAR T-Cell Therapy Market Perspective (2020-2031)

2.2 Global CAR T-Cell Therapy Growth Trends by Region

2.2.1 Global CAR T-Cell Therapy Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 CAR T-Cell Therapy Historic Market Size by Region (2020-2025)

2.2.3 CAR T-Cell Therapy Forecasted Market Size by Region (2026-2031)

2.3 CAR T-Cell Therapy Market Dynamics

2.3.1 CAR T-Cell Therapy Industry Trends

2.3.2 CAR T-Cell Therapy Market Drivers

2.3.3 CAR T-Cell Therapy Market Challenges

2.3.4 CAR T-Cell Therapy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top CAR T-Cell Therapy Players by Revenue

3.1.1 Global Top CAR T-Cell Therapy Players by Revenue (2020-2025)

3.1.2 Global CAR T-Cell Therapy Revenue Market Share by Players (2020-2025)

3.2 Global CAR T-Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by CAR T-Cell Therapy Revenue

3.4 Global CAR T-Cell Therapy Market Concentration Ratio

3.4.1 Global CAR T-Cell Therapy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by CAR T-Cell Therapy Revenue in 2024

3.5 Global Key Players of CAR T-Cell Therapy Head office and Area Served

3.6 Global Key Players of CAR T-Cell Therapy, Product and Application

3.7 Global Key Players of CAR T-Cell Therapy, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 CAR T-Cell Therapy Breakdown Data by Type

4.1 Global CAR T-Cell Therapy Historic Market Size by Type (2020-2025)

4.2 Global CAR T-Cell Therapy Forecasted Market Size by Type (2026-2031)

5 CAR T-Cell Therapy Breakdown Data by Application

5.1 Global CAR T-Cell Therapy Historic Market Size by Application (2020-2025)

5.2 Global CAR T-Cell Therapy Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America CAR T-Cell Therapy Market Size (2020-2031)

6.2 North America CAR T-Cell Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America CAR T-Cell Therapy Market Size by Country (2020-2025)

6.4 North America CAR T-Cell Therapy Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe CAR T-Cell Therapy Market Size (2020-2031)

7.2 Europe CAR T-Cell Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe CAR T-Cell Therapy Market Size by Country (2020-2025)

7.4 Europe CAR T-Cell Therapy Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific CAR T-Cell Therapy Market Size (2020-2031)

8.2 Asia-Pacific CAR T-Cell Therapy Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific CAR T-Cell Therapy Market Size by Region (2020-2025)

8.4 Asia-Pacific CAR T-Cell Therapy Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America CAR T-Cell Therapy Market Size (2020-2031)

9.2 Latin America CAR T-Cell Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America CAR T-Cell Therapy Market Size by Country (2020-2025)

9.4 Latin America CAR T-Cell Therapy Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa CAR T-Cell Therapy Market Size (2020-2031)

10.2 Middle East & Africa CAR T-Cell Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa CAR T-Cell Therapy Market Size by Country (2020-2025)

10.4 Middle East & Africa CAR T-Cell Therapy Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Details

11.1.2 Novartis Business Overview

11.1.3 Novartis CAR T-Cell Therapy Introduction

11.1.4 Novartis Revenue in CAR T-Cell Therapy Business (2020-2025)

11.1.5 Novartis Recent Development

11.2 Gilead Sciences

11.2.1 Gilead Sciences Company Details

11.2.2 Gilead Sciences Business Overview

11.2.3 Gilead Sciences CAR T-Cell Therapy Introduction

11.2.4 Gilead Sciences Revenue in CAR T-Cell Therapy Business (2020-2025)

11.2.5 Gilead Sciences Recent Development

11.3 Bristol-Myers Squibb

11.3.1 Bristol-Myers Squibb Company Details

11.3.2 Bristol-Myers Squibb Business Overview

11.3.3 Bristol-Myers Squibb CAR T-Cell Therapy Introduction

11.3.4 Bristol-Myers Squibb Revenue in CAR T-Cell Therapy Business (2020-2025)

11.3.5 Bristol-Myers Squibb Recent Development

11.4 J & J

11.4.1 J & J Company Details

11.4.2 J & J Business Overview

11.4.3 J & J CAR T-Cell Therapy Introduction

11.4.4 J & J Revenue in CAR T-Cell Therapy Business (2020-2025)

11.4.5 J & J Recent Development

11.5 JW Therapeutics

11.5.1 JW Therapeutics Company Details

11.5.2 JW Therapeutics Business Overview

11.5.3 JW Therapeutics CAR T-Cell Therapy Introduction

11.5.4 JW Therapeutics Revenue in CAR T-Cell Therapy Business (2020-2025)

11.5.5 JW Therapeutics Recent Development

11.6 FOSUNKite

11.6.1 FOSUNKite Company Details

11.6.2 FOSUNKite Business Overview

11.6.3 FOSUNKite CAR T-Cell Therapy Introduction

11.6.4 FOSUNKite Revenue in CAR T-Cell Therapy Business (2020-2025)

11.6.5 FOSUNKite Recent Development

11.7 CARsgen Therapeutics (Pipeline)

11.7.1 CARsgen Therapeutics (Pipeline) Company Details

11.7.2 CARsgen Therapeutics (Pipeline) Business Overview

11.7.3 CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Introduction

11.7.4 CARsgen Therapeutics (Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)

11.7.5 CARsgen Therapeutics (Pipeline) Recent Development

11.8 Autolus Therapeutics(Pipeline)

11.8.1 Autolus Therapeutics(Pipeline) Company Details

11.8.2 Autolus Therapeutics(Pipeline) Business Overview

11.8.3 Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Introduction

11.8.4 Autolus Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)

11.8.5 Autolus Therapeutics(Pipeline) Recent Development

11.9 Sorrento Therapeutics(Pipeline)

11.9.1 Sorrento Therapeutics(Pipeline) Company Details

11.9.2 Sorrento Therapeutics(Pipeline) Business Overview

11.9.3 Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Introduction

11.9.4 Sorrento Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)

11.9.5 Sorrento Therapeutics(Pipeline) Recent Development

11.10 Mustang Bio(Pipeline)

11.10.1 Mustang Bio(Pipeline) Company Details

11.10.2 Mustang Bio(Pipeline) Business Overview

11.10.3 Mustang Bio(Pipeline) CAR T-Cell Therapy Introduction

11.10.4 Mustang Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)

11.10.5 Mustang Bio(Pipeline) Recent Development

11.11 Bluebird Bio(Pipeline)

11.11.1 Bluebird Bio(Pipeline) Company Details

11.11.2 Bluebird Bio(Pipeline) Business Overview

11.11.3 Bluebird Bio(Pipeline) CAR T-Cell Therapy Introduction

11.11.4 Bluebird Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)

11.11.5 Bluebird Bio(Pipeline) Recent Development

11.12 Cellectis(Pipeline)

11.12.1 Cellectis(Pipeline) Company Details

11.12.2 Cellectis(Pipeline) Business Overview

11.12.3 Cellectis(Pipeline) CAR T-Cell Therapy Introduction

11.12.4 Cellectis(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)

11.12.5 Cellectis(Pipeline) Recent Development

11.13 Allogene Therapeutics(Pipeline)

11.13.1 Allogene Therapeutics(Pipeline) Company Details

11.13.2 Allogene Therapeutics(Pipeline) Business Overview

11.13.3 Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Introduction

11.13.4 Allogene Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)

11.13.5 Allogene Therapeutics(Pipeline) Recent Development

11.14 Celyad(Pipeline)

11.14.1 Celyad(Pipeline) Company Details

11.14.2 Celyad(Pipeline) Business Overview

11.14.3 Celyad(Pipeline) CAR T-Cell Therapy Introduction

11.14.4 Celyad(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025)

11.14.5 Celyad(Pipeline) Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

CARsgen Therapeutics (Pipeline)

Autolus Therapeutics(Pipeline)

Sorrento Therapeutics(Pipeline)

Mustang Bio(Pipeline)

Bluebird Bio(Pipeline)

Cellectis(Pipeline)

Allogene Therapeutics(Pipeline)

Celyad(Pipeline)

Gilead Sciences

Novartis

List of Tables

Table 1. Global CAR T-Cell Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of CD19 - Targeted

Table 3. Key Players of BCMA - Targeted

Table 4. Global CAR T-Cell Therapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global CAR T-Cell Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global CAR T-Cell Therapy Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global CAR T-Cell Therapy Market Share by Region (2020-2025)

Table 8. Global CAR T-Cell Therapy Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global CAR T-Cell Therapy Market Share by Region (2026-2031)

Table 10. CAR T-Cell Therapy Market Trends

Table 11. CAR T-Cell Therapy Market Drivers

Table 12. CAR T-Cell Therapy Market Challenges

Table 13. CAR T-Cell Therapy Market Restraints

Table 14. Global CAR T-Cell Therapy Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global CAR T-Cell Therapy Market Share by Players (2020-2025)

Table 16. Global Top CAR T-Cell Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR T-Cell Therapy as of 2024)

Table 17. Ranking of Global Top CAR T-Cell Therapy Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by CAR T-Cell Therapy Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of CAR T-Cell Therapy, Headquarters and Area Served

Table 20. Global Key Players of CAR T-Cell Therapy, Product and Application

Table 21. Global Key Players of CAR T-Cell Therapy, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global CAR T-Cell Therapy Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global CAR T-Cell Therapy Revenue Market Share by Type (2020-2025)

Table 25. Global CAR T-Cell Therapy Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global CAR T-Cell Therapy Revenue Market Share by Type (2026-2031)

Table 27. Global CAR T-Cell Therapy Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global CAR T-Cell Therapy Revenue Market Share by Application (2020-2025)

Table 29. Global CAR T-Cell Therapy Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global CAR T-Cell Therapy Revenue Market Share by Application (2026-2031)

Table 31. North America CAR T-Cell Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America CAR T-Cell Therapy Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America CAR T-Cell Therapy Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe CAR T-Cell Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe CAR T-Cell Therapy Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe CAR T-Cell Therapy Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific CAR T-Cell Therapy Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific CAR T-Cell Therapy Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific CAR T-Cell Therapy Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America CAR T-Cell Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America CAR T-Cell Therapy Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America CAR T-Cell Therapy Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa CAR T-Cell Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa CAR T-Cell Therapy Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa CAR T-Cell Therapy Market Size by Country (2026-2031) & (US$ Million)

Table 46. Novartis Company Details

Table 47. Novartis Business Overview

Table 48. Novartis CAR T-Cell Therapy Product

Table 49. Novartis Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 50. Novartis Recent Development

Table 51. Gilead Sciences Company Details

Table 52. Gilead Sciences Business Overview

Table 53. Gilead Sciences CAR T-Cell Therapy Product

Table 54. Gilead Sciences Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 55. Gilead Sciences Recent Development

Table 56. Bristol-Myers Squibb Company Details

Table 57. Bristol-Myers Squibb Business Overview

Table 58. Bristol-Myers Squibb CAR T-Cell Therapy Product

Table 59. Bristol-Myers Squibb Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 60. Bristol-Myers Squibb Recent Development

Table 61. J & J Company Details

Table 62. J & J Business Overview

Table 63. J & J CAR T-Cell Therapy Product

Table 64. J & J Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 65. J & J Recent Development

Table 66. JW Therapeutics Company Details

Table 67. JW Therapeutics Business Overview

Table 68. JW Therapeutics CAR T-Cell Therapy Product

Table 69. JW Therapeutics Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 70. JW Therapeutics Recent Development

Table 71. FOSUNKite Company Details

Table 72. FOSUNKite Business Overview

Table 73. FOSUNKite CAR T-Cell Therapy Product

Table 74. FOSUNKite Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 75. FOSUNKite Recent Development

Table 76. CARsgen Therapeutics (Pipeline) Company Details

Table 77. CARsgen Therapeutics (Pipeline) Business Overview

Table 78. CARsgen Therapeutics (Pipeline) CAR T-Cell Therapy Product

Table 79. CARsgen Therapeutics (Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 80. CARsgen Therapeutics (Pipeline) Recent Development

Table 81. Autolus Therapeutics(Pipeline) Company Details

Table 82. Autolus Therapeutics(Pipeline) Business Overview

Table 83. Autolus Therapeutics(Pipeline) CAR T-Cell Therapy Product

Table 84. Autolus Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 85. Autolus Therapeutics(Pipeline) Recent Development

Table 86. Sorrento Therapeutics(Pipeline) Company Details

Table 87. Sorrento Therapeutics(Pipeline) Business Overview

Table 88. Sorrento Therapeutics(Pipeline) CAR T-Cell Therapy Product

Table 89. Sorrento Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 90. Sorrento Therapeutics(Pipeline) Recent Development

Table 91. Mustang Bio(Pipeline) Company Details

Table 92. Mustang Bio(Pipeline) Business Overview

Table 93. Mustang Bio(Pipeline) CAR T-Cell Therapy Product

Table 94. Mustang Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 95. Mustang Bio(Pipeline) Recent Development

Table 96. Bluebird Bio(Pipeline) Company Details

Table 97. Bluebird Bio(Pipeline) Business Overview

Table 98. Bluebird Bio(Pipeline) CAR T-Cell Therapy Product

Table 99. Bluebird Bio(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 100. Bluebird Bio(Pipeline) Recent Development

Table 101. Cellectis(Pipeline) Company Details

Table 102. Cellectis(Pipeline) Business Overview

Table 103. Cellectis(Pipeline) CAR T-Cell Therapy Product

Table 104. Cellectis(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 105. Cellectis(Pipeline) Recent Development

Table 106. Allogene Therapeutics(Pipeline) Company Details

Table 107. Allogene Therapeutics(Pipeline) Business Overview

Table 108. Allogene Therapeutics(Pipeline) CAR T-Cell Therapy Product

Table 109. Allogene Therapeutics(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 110. Allogene Therapeutics(Pipeline) Recent Development

Table 111. Celyad(Pipeline) Company Details

Table 112. Celyad(Pipeline) Business Overview

Table 113. Celyad(Pipeline) CAR T-Cell Therapy Product

Table 114. Celyad(Pipeline) Revenue in CAR T-Cell Therapy Business (2020-2025) & (US$ Million)

Table 115. Celyad(Pipeline) Recent Development

Table 116. Research Programs/Design for This Report

Table 117. Key Data Information from Secondary Sources

Table 118. Key Data Information from Primary Sources

Table 119. Authors List of This Report

List of Figures

Figure 1. CAR T-Cell Therapy Picture

Figure 2. Global CAR T-Cell Therapy Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global CAR T-Cell Therapy Market Share by Type: 2024 VS 2031

Figure 4. CD19 - Targeted Features

Figure 5. BCMA - Targeted Features

Figure 6. Global CAR T-Cell Therapy Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global CAR T-Cell Therapy Market Share by Application: 2024 VS 2031

Figure 8. Lymphoma Case Studies

Figure 9. Multiple Myeloma Case Studies

Figure 10. CAR T-Cell Therapy Report Years Considered

Figure 11. Global CAR T-Cell Therapy Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 12. Global CAR T-Cell Therapy Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global CAR T-Cell Therapy Market Share by Region: 2024 VS 2031

Figure 14. Global CAR T-Cell Therapy Market Share by Players in 2024

Figure 15. Global Top CAR T-Cell Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR T-Cell Therapy as of 2024)

Figure 16. The Top 10 and 5 Players Market Share by CAR T-Cell Therapy Revenue in 2024

Figure 17. North America CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 18. North America CAR T-Cell Therapy Market Share by Country (2020-2031)

Figure 19. United States CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. Canada CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Europe CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe CAR T-Cell Therapy Market Share by Country (2020-2031)

Figure 23. Germany CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. France CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. U.K. CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Italy CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Russia CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Nordic Countries CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Asia-Pacific CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific CAR T-Cell Therapy Market Share by Region (2020-2031)

Figure 31. China CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Japan CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. South Korea CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Southeast Asia CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. India CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Australia CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Latin America CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America CAR T-Cell Therapy Market Share by Country (2020-2031)

Figure 39. Mexico CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Brazil CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Middle East & Africa CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa CAR T-Cell Therapy Market Share by Country (2020-2031)

Figure 43. Turkey CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Saudi Arabia CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. UAE CAR T-Cell Therapy Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Novartis Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 47. Gilead Sciences Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 48. Bristol-Myers Squibb Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 49. J & J Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 50. JW Therapeutics Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 51. FOSUNKite Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 52. CARsgen Therapeutics (Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 53. Autolus Therapeutics(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 54. Sorrento Therapeutics(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 55. Mustang Bio(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 56. Bluebird Bio(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 57. Cellectis(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 58. Allogene Therapeutics(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 59. Celyad(Pipeline) Revenue Growth Rate in CAR T-Cell Therapy Business (2020-2025)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions